Why Are ATyr Pharma's Shares Trading Higher Today?

  • ATyr Pharma Inc LIFE has announced positive results from its Phase 1b/2a trial evaluating its lead therapeutic candidate, ATYR1923, in pulmonary sarcoidosis, a major form of interstitial lung disease.
  • In 37 patients, ATYR1923 was safe and well-tolerated at all doses with no drug-related serious adverse events or signal of immunogenicity.
  • Additionally, the study demonstrated consistent dose-response for ATYR1923 on key efficacy endpoints and improvements compared to placebo, including steroid reduction, lung function, sarcoidosis symptom measures, and inflammatory biomarkers.
  • Steroid reduction of 58% overall from baseline and 22% relative reduction compared to placebo in steroid usage post taper in the 5.0 mg/kg treatment group was observed.
  • The absolute improvement in forced vital capacity (FVC) measured lung function at week 24 of 3.3% in the 5.0 mg/kg treatment group compared to placebo.
  • Price Action: LIFE shares are up 9.12% at $5.98 during the market session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechLong IdeasNewsHealth CareMoversTrading IdeasGeneralBriefsPhase 1 TrialSarcoidosiswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!